FDA Approval Is “First Action” For 32% Of NMEs; Rate Less Than Other NDAs
Executive Summary
FDA approved approximately one-third of new molecular entities with user fee deadlines in 2002 during the first cycle
You may also be interested in...
FDA First-Cycle Approval Rate For NMEs Leaps To 50% In 2003
FDA's effort to increase the rate that drug products are approved by their user fee goal date appears to be paying off, with significant improvement seen in 2003 compared to the year before
FDA First-Cycle Approval Rate For NMEs Leaps To 50% In 2003
FDA's effort to increase the rate that drug products are approved by their user fee goal date appears to be paying off, with significant improvement seen in 2003 compared to the year before
FDA Approves 9 NMEs, 6 BLAs In First Half ‘03, On Track To Exceed 2002 Total
FDA closed out the first half of 2003 with nine new molecular entities and six major biologic approvals, putting the agency well ahead of where it was at the same time last year, according to an analysis by F-D-C Reports' Pharmaceutical Approvals Monthly